Image by Ri Butov from Pixabay
The United States has announced a narrow exemption from its new 100% tariff on certain patented pharmaceutical products imported from India and 19 other partner jurisdictions. The decision provides important relief to parts of the global pharmaceutical industry, especially manufacturers supplying medicines for rare diseases, fertility treatment, cancer care and advanced therapies.
However, the exemption is not a blanket waiver for every medicine exported from these countries. It applies only to clearly defined categories of specialty pharmaceutical products and related ingredients. Companies must also meet the conditions set out in the new US trade and customs framework.
The move comes as Washington attempts to encourage more pharmaceutical manufacturing within the United States. At the same time, the government appears to recognise that imposing very high duties on certain essential or highly specialised medicines could disrupt patient care and put pressure on hospitals, doctors and healthcare systems.
What is the 100% tariff?
A tariff is a tax imposed on goods entering a country. In this case, the United States has introduced a tariff equal to 100% of the value of certain imported patented pharmaceutical products.
For example, if a covered medicine is worth ₹100 or $100 before entering the United States, a 100% tariff could add another ₹100 or $100 to its import cost. The importer may then pass that additional cost through the supply chain. Eventually, the impact could be felt by drug distributors, hospitals, insurers and patients.
The measure was introduced under Section 232 of the US Trade Expansion Act. This law allows the US government to impose trade restrictions when it believes imports may affect national security. The administration has argued that the country needs greater control over its pharmaceutical supply chain and must reduce dependence on foreign production.
The tariff mainly affects specified patented drugs, biologics and pharmaceutical ingredients. Generic medicines and their ingredients remain outside the Section 232 pharmaceutical tariffs, according to the reported guidance.
The distinction between patented and generic medicines is important. Patented drugs are generally protected by intellectual-property rights and are often sold under brand names. Generic medicines contain the same active ingredients as corresponding branded drugs but are usually sold after patent protection expires, often at lower prices. India is one of the jurisdictions covered by the zero-tariff framework.
What does this mean for India?
For India, the exemption is a positive development, particularly for companies involved in specialty medicines, advanced therapies and pharmaceutical ingredients.
It may protect Indian exporters from a sudden increase in the cost of supplying eligible products to the US market. It may also preserve existing commercial relationships between Indian manufacturers, American distributors and healthcare providers.
However, the benefit will differ from company to company. Firms focused mainly on generic medicines were already outside the new tariff framework, while businesses producing patented medicines must check whether their products fall within an approved category.
Indian manufacturers will also need to follow US customs, regulatory and documentation requirements carefully. A product may be made in India but still fail to qualify if it does not meet the technical definition of a covered specialty medicine.
A careful balance between trade and healthcare
The US decision represents an attempt to balance two competing objectives. On one side is the goal of increasing domestic pharmaceutical production and reducing dependence on overseas supply chains. On the other is the need to ensure that patients continue to receive essential medicines at reasonable prices.
A 100% tariff could have been especially damaging for medicines that are difficult to replace, produced by only a few manufacturers or required by small patient groups. The exemptions reduce that risk, but they do not remove all uncertainty.
The policy remains narrow and complex. Companies will need to study the rules product by product rather than relying only on their country of origin. For India’s pharmaceutical industry, the decision offers meaningful relief, but it is best understood as a targeted exemption, not a broad escape from US tariffs.
References